The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)

  title={The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)},
  author={A. Richard Green and Annis O. Mechan and J. Martin Elliott and Esther O'Shea and Mar{\'i}a Isabel Colado},
  journal={Pharmacological Reviews},
  pages={463 - 508}
The amphetamine derivative (±)-3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is a popular recreational drug among young people, particularly those involved in the dance culture. MDMA produces an acute, rapid enhancement in the release of both serotonin (5-HT) and dopamine from nerve endings in the brains of experimental animals. It produces increased locomotor activity and the serotonin behavioral syndrome in rats. Crucially, it produces dose-dependent hyperthermia that is potentially fatal… 

Figures and Tables from this paper

Interactions between 3,4-Methylenedioxymethamphetamine and Ethanol in Humans and Rodents
The possibility that EtOH may modify the pharmacokinetics and pharmadynamics of MDMA is of concern in terms of liability for misuse abuse and this short review focuses on the known interactions between MDMA and EtOH in humans and rodents.
Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons
3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings
MDMA-induced 5- HT depletions are not necessarily synonymous with neurotoxic damage, however, doses of MDMA which do not cause long-term 5-HT depletion can have protracted effects on behavior, suggesting even moderate doses of the drug may pose risks.
The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis
The aim of this review is to address both sides of the MDMA-neurotoxicity controversy, including recent findings from the laboratory regarding the potential of MDMA to induce serotonergic damage in a rat binge model, and to add to the growing literature implicating neuroregulatory mechanisms underlying MDMA-induced Serotonergic dysfunction.
3,4-methylenedioxymethamphetamine (MDMA): current perspectives
  • J. Meyer
  • Psychology, Biology
    Substance abuse and rehabilitation
  • 2013
MDMA-assisted psychotherapy for patients with chronic, treatment-resistant posttraumatic stress disorder is currently under investigation, and initial results show efficacy for this treatment approach, although considerably more research must be performed to confirm such efficacy and to ensure that the benefits of MDMA-assisted therapy outweigh the risks to the patients.


Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”)
It is suggested that the recent increase in the number of reports of MDMA toxicity probably results from the widespread use of the drug at all night dance parties or “raves”, and suggestions for the rational treatment of the acute toxicity are made on the basis of both pharmacological studies in animals and current clinical practice.
3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys.
Data demonstrating potent and selective effects of MDMA on various brain serotonin parameters in rhesus monkeys suggest that the drug may produce similar effects in humans.
Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans
Differences in personality support the view that 5-HT systems are involved in modulating impulsive and aggressive personality traits and suggest that5-HT neurotoxicity may be a potential complication of MDMA use.
(+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates.
Results indicate that MDMA is a selective serotonergic neurotoxin in nonhuman primates and that humans using this drug may be at risk for incurring central Serotonergic neuronal damage.
Neurochemistry and Neurotoxicity of 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
The following review attempts to provide a brief summary of recent data on the neurochemistry and neurotoxicity of MDMA and its derivatives.
Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate.
It is indicated that at doses only 2-3 times the human dose, MDMA produces significant forebrain 5-HT decreases but does not produce detectable residual behavioral alterations as assessed by these behavioral paradigms.
Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’)
As the popularity of MDMA has increased, so have reports of adverse nonpsychiatric and psychiatric consequences associated with use of the drug, and it is possible that some individuals with no apparent abnormalities might develop complications over time.
Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users
The present data indicate that MDMA users have alterations in 5-HT neuronal function, possibly as a consequence of MDMA-induced brain serotonin neural injury.
Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the wistar rat